Wolf J, Mazieres J, Oh IJ, et al. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated alk+ non-small-cell lung cancer (NSCLC). ESMO 2017, abstract 1299O_PR.,Gadgeel S, Peters S, Mok T, et al. Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study. ESMO1298O_PR.
RA-patiënt met kanker kan veilig worden behandeld met checkpointremmer
mei 2023 | Dermato-oncologie, Immuuntherapie, Longoncologie, RA